Injectable contraceptives are the most widely used method of contraception in sub-Saharan
Africa among married or in-union women aged 15–44 [
[1]
]. Injectable contraceptive use grew more quickly than use of any other contraceptive
method between 1994 and 2015: from 2% to 7% of the share of all contraceptive use
(among married or in-union women) worldwide, and from 17% to 38% of the share of all
contraceptive use in sub-Saharan Africa [
[1]
]. Injectables are quick to administer, highly effective, do not require daily user
action, and can be used clandestinely [
[2]
]. Like all contraceptive methods, injectables can empower women and couples to achieve
their reproductive goals, reduce unintended pregnancy, and prevent maternal morbidity
and mortality [
[3]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Trends in contraceptive use worldwide 2015 (ST/ESA/SER.A/349).2015
- Rising popularity of injectable contraceptives in sub-Saharan Africa.Afr Popul Stud. 2011; 25: 587-604
- Maternal deaths averted by contraceptive use: an analysis of 172 countries.Lancet. 2012; 380: 111-125
- An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.AIDS. 2016; 30: 2665-2683
- Hormonal contraceptive eligibility for women at high risk of HIV. Guidance statement: Recommendations concerning the use of hormonal contraceptive methods by women at high risk of HIV.World Health Organization, Geneva, Switzerland2017
- Contraceptive efficacy and safety of DMPA-SC.Contraception. 2004; 70: 269-275
- Subcutaneous versus intramuscular depot methoxyprogesterone acetate: a comparative review.Womens Health (Lond). 2006; 2: 191-197
- Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.Contraception. 2009; 80: 7-17
- The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): a systematic review.Contraception. 2016; 94: 202-215
- Subcutaneous DMPA: a better lower dose approach.Contraception. 2014; 89: 341-343
- Sayana® press: can it be a “game changer" for reducing unmet need for family planning?.Contraception. 2014; 89: 335-338
- Advocacy pack for subcutaneous DMPA.PATH, Washington, DC2017 ([Accessed July 6, 2017])
- Observational study of the acceptability of Sayana® press among intramuscular DMPA users in Uganda and Senegal.Contraception. 2014; 89: 361-367
- Preference for Sayana® press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.Contraception. 2014; 89: 385-395
- Provider acceptability of Sayana® press: results from community health workers and clinic-based providers in Uganda and Senegal.Contraception. 2014; 89: 368-373
- Perceptions of home and self-injection of Sayana® Press in Ethiopia: a qualitative study.Contraception. 2014; 89: 379-384
- Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.Contraception. 2016; 94: 303-313
- Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.Contraception. 2012; 85: 453-457
- Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.Contraception. 2012; 85: 458-464
- The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.Contraception. 2016; 94: 314-320
- Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.Contraception. 2014; 89: 352-356
- Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.Contraception. 2013; 88: 401-407
- Sayana® press study evaluating suitability for self-injection.(Available from:)https://www.fhi360.org/projects/sayana%C2%AE-press-study-evaluating-suitability-self-injectionDate: 2014Date accessed: October 31, 2016
- Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches.AIDS. 2013; 27: S35-43
- Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.PLoS Med. 2015; 12: e1001778
- Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.Lancet Infect Dis. 2015; 15: 181-189
- Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.Endocr Rev. 2010; 31: 79-97
- Research gaps in defining the biological link between HIV risk and hormonal contraception.Am J Reprod Immunol. 2014; 72: 228-235
U.S. Food and Drug Administration. Depo-SubQ Provera 104 (Medroxyprogesterone Acetate) Injectable Suspension New Drug Application No.: 021583. Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics Review; 2014.
- Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.Contraception. 2016; 94: 40-47
- Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.Contraception. 2004; 70: 11-18
- Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women.Clin Ther. 2004; 26: 1845-1854
- Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper arm.Contraception. Elsevier Inc., 2014: 31-35
- Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.J Clin Endocrinol Metab. 1977; 44: 32-38
- Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.Acta Endocrinol. 1982; 99: 339-343
- A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.Fertil Steril. 1980; 34: 131-139
- Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.Fertil Steril. 2008; 90: 965-971
- A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females.Contraception. 2014; 89: 357-360
- Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera).Contraception. 1974; 10: 39-45
- Injected long--acting medroxyprogesterone acetate. Effect on human lactation and concentrations in milk.J Med Assoc Thail. 1977; 60: 57-60
- A radioimmunoassay for serum medroxyprogesterone acetate.J Steroid Biochem. 1978; 9: 359-363
- Pharmacokinetic study of different doses of Depo Provera.Contraception. 1980; 22: 527-536
- Metabolism of injectable formulations of contraceptive steroids in obese and thin women.Contraception. 1982; 26: 51-58
- Concentration changes of medroxyprogesterone acetate in serum and milk in lactating woman who used Depo Geston®.J Reprod Contracept. 2004; 15: 157-162
- Pharmacodynamic effects of depot-medroxyprogesterone acetate (DMPA) administered to lactating women on their male infants.Contraception. 1996; 54: 153-157
- Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of Depo-ProveraR to women.Contraception. 1976; 14: 461-469
- Medroxyprogesterone acetate in human serum.J Steroid Biochem. 1981; 14: 783-786
- Serum medroxyprogesterone acetate levels in new and repeat users of depot medroxyprogesterone acetate at the end of the dosing interval.Contraception. 2004; 69: 3-7
- Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses.Fertil Steril. 1984; 42: 216-222
- Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.Clin Pharmacol Ther. 2007; 81: 222-227
- Pharmacokinetics of depot medroxyprogesterone acetate contraception.J Reprod Med. 1996; 41: 381-390
- Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.Steroids. 2011; 76: 636-652
- Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.Endocr Rev. 2013; 34: 171-208
- Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interaction.Mol Cell Endocrinol. 2009; 299: 219-231
- CCR5 expression levels in HIV-uninfected women receiving hormonal contraception.J Infect Dis. 2015; 212: 1397-1401
- Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study.Lancet Infect Dis. 2016; 16: 441-448
- Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.J Acquir Immune Defic Syndr. 2015; 68: 511-518
- Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.Endocrinology. 2013; 154: 1282-1295
- Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.Mucosal Immunol. 2016; 9: 1571-1583
- Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.J Reprod Immunol. 2015; 110: 14-21
- Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract.Am J Reprod Immunol. 2015; 74: 357-367
- Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion.J Acquir Immune Defic Syndr. 2014; 66: 109-117
- The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception.MBio. 2015; 6: e00221-15
- Progestin-containing contraceptives alter expression of host defense-related genes of the endometrium and cervix.Reprod Sci. 2015; 22: 814-828
- Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users.Fertil Steril. 2008; 90: 872-875
- Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium.Fertil Steril. 2003; 79: 856-863
- A depot medroxyprogesterone acetate dose that models human use and its effect on vaginal SHIV acquisition risk.J Acquir Immune Defic Syndr. 2016; 72: 363-371
- The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with mycobacterium tuberculosis.Infect Immun. 2013; 81: 1234-1244
- Dendritic cell function and pathogen-specific T cell immunity are inhibited in mice administered levonorgestrel prior to intranasal chlamydia trachomatis infection.Sci Rep. 2016; 6: 37723
- Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2.J Virol. 2003; 77: 9845-9851
- Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection.J Immunol. 2012; 189: 3449-3461
- Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.AIDS. 2015; 29: 1137-1146
- Medroxyprogesterone acetate impairs human dendritic cell activation and function.Hum Reprod. 2015; 30: 1169-1177
- Medroxyprogesterone acetate regulates HIV-1 uptake and transcytosis but not replication in primary genital epithelial cells, resulting in enhanced T-cell infection.J Infect Dis. 2015; 211: 1745-1756
- The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor.PLoS One. 2014; 9: e96497
- Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner.J Biol Chem. 2014; 289: 31136-31149
- The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor.PLoS One. 2013; 8: e62895
- Synthetic progestins used in HRT have different glucocorticoid agonist properties.Mol Cell Endocrinol. 2005; 242: 23-32
- Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells.Mol Cell Endocrinol. 2004; 221: 75-85
- Investigating the anti-mineralocorticoid properties of synthetic progestins used in hormone therapy.Biochem Biophys Res Commun. 2013; 433: 305-310
- A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A).J Steroid Biochem Mol Biol. 2014; 143: 404-415
- New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.Mol Endocrinol. 2001; 15: 255-270
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.Steroids. 2008; : 222-231
- Medroxyprogesterone acetate alters mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users.PLoS ONE. Public Library of Science, 2011: e24639
- Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy.Proc Natl Acad Sci U S A. 2017; 114: E181-E190
- GraphPad curve fitting guide.http://www.graphpad.com/guides/prism/7/curve-fitting/index.htmDate accessed: May 3, 2016
Article info
Publication history
Published online: December 11, 2017
Accepted:
December 2,
2017
Received in revised form:
November 18,
2017
Received:
July 25,
2017
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
